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Implementation Group (NRIG) was established to implement these 
recommendations. 
The NRAG model of radiotherapy demand was seen asoverambitious 
and unrealistic and the Malthus Programme was commissioned to 
review and update the work. Malthus is an academic initiative to 
provide adiscrete event tool for simulation of radiotherapy demand in 
the U.K. at alocal level. Launched in October 2011, the tool provides 
radiotherapy service managers and healthcare commissioners with a 
customisable tool that can quantify radiotherapy demand at the level 
of the primary care trust (mean population = 330,000) or cancer 
network (mean population = 2,300,000). Clinical decision making is 
encoded into disease specific decision trees, established by a review 
of current evidence based practice for radiotherapy. The tool uses 
curated data feeds from the national cancer intelligence network to 
provide accurate local population demographic and cancer incidence 
data. Models for population growth and change in cancer incidence 
are used to forecast radiotherapy demand through to 2030. The 
estimate of radiotherapy demand forthe U.K as a whole for 2016 is 
55,000 fractions per million, closely similar to that of NRAG. To 
encourage expansion of radiotherapy there is now a nationallyagreed 
tariff and the service will be commissioned nationally 
The Radiotherapy Dataset (RTDS) collates information on treatment 
activity via electronic feeds from all radiotherapy centres in England. 
Monthly data uploads have been mandatory since April 2009, and 
datafeeds from RTDS are available with a 12 month latency from the 
Cancer Commissioning Toolkit. These data can be compared to the 
Malthus model in order  to understand radiotherapy provision for the 
local population. As local data on stage and performance status 
become available it will be possible to assess the influence of these 
factors on the uptake of radiotherapy and whether or not they have a 
significant influence in addition to under-investment. 
IMRT delivery has increased from 2% of patients in 2008 to 11% of all 
patients in 2012. It is expected that IMRT will be offered to the 33% of 
radically treated patients who would benefit by the end of 2013. A 
national programme to support IMRT training, implementation, and 
quality assurance has been established to overcome the barriers 
including staff shortages, lack of agreed funding for IMRT, and low 
levels of training in IMRT implementation. The expansion of IGRT will 
then pave the way to the development of 4D adaptive radiotherapy as 
envisaged in the NRAG report of 2007. 
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Based on detailed evidence-based modeling, radiotherapy has been 
identified as a necessary component of the oncological treatment in 
on average 52% of allnewly diagnosed cancer patients. Such estimates 
are important to help forecast radiotherapy resource and personnel 
needs. But when applied to different countries, such as in the highly 
variable European context, one should be aware that they are sensi-
tive to the demographic and socio-economic factors in these countries 
and to changes in incidence, population mix and stage distribution 
over time. 
In the early years 2000, the ESTRO-QUARTS-project used a combina-
tion of epidemiology, evidence-based radiotherapy indications and 
resource use to evaluate the differences in needs amongst 23 Euro-
pean countries. Along with this modelling exercise, it also suggested 
benchmarks for infrastructure and personnel requirements. 
Although extremely valuable, these data only represented a snapshot 
in time. To be of practical help for the European countries to support 
their radiotherapy training programmes and infrastructure projec-
tion,they do not only need regular update and correction for the 
changing cancer incidence and demographics, they should also take 
the evolving evidence on radiotherapy indications, utilisation and 
complexity into account. Furthermore,there is an urgent need for 
accurate data on infrastructure and personnel availability, to put the 
estimated needs into the correct perspective.  
Hence, almost a decade later, ESTRO has launched the HERO-project 
(Health Economics in Radiation Oncology), of which the overall aim is 
to develop a knowledge base and a model for health economic evalua-
tion of radiation treatments at the European level.  
As a first task in the project, a validated and detailed blueprint of the 
present situation of radiotherapy in Europe is made in terms of cancer 
incidence, number of centres, equipment and personnel and of reim-
bursement. Furthermore, a refinement of the QUARTS analysis on the 
needs is carried out, based on modelling exercises incorporating the 
most recent evidence-based utilisation estimates of CCORE.  
Apart from supporting the European countries and national societies 
within radiotherapy and oncology in their strive for optimal radiothe-
rapy capacity planning, these data will be used to feed nation-based 
cost-accounting models for radiotherapy. Finally, these data will also 
form the basis for cost-effectiveness analyses to evaluate the value 
for money of radiotherapy innovations and of radiotherapy compared 
to other oncologic treatments. 
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Because of inevitable uncertainties in RT, margins assure that the 
prescribed dose is actually absorbed in the target. A major 
breakthrough in thinking about margins occurred with the appearance 
of ICRU50, standardizing terminology. Around the same time, random 
errors, that affect each treatment fraction differently, and systematic 
errors that affect all fractions in the same way were differentiated. A 
second breakthrough occurred in the second half of the nineties when 
it was realized that you have to make a trade-off between the risk of 
underdosing the target that reduces with bigger margins, versus the 
risk of overdosing normal tissues that increases with bigger margins. 
This trade-off is then expressed is the probability of a certain 
underdose of the target. Using then plausible uncertainty data for the 
prostate, it appeared that a 90% probability of delivering 95% of the 
prescribed dose in the target required a then routine 1 cm margin. 
I.e., these numbers were apparently clinically acceptable and they 
formed the basis for the (simplified) NKI margin recipe: M = 2.5 SIGMA 
+ 0.7 sigma. Many authors have challenged and refined this 
publication but it it is still being widely used. The equations works 
well for a wide range of situations and are safe if you adjust the 
SIGMA and sigma for the number of fractions given.  
Then what are the problems with margins? First, they do not take the 
beam and patient geometry into account. E.g., a high dose is assumed 
even where the margin overlap an organ at risk, while the probability 
of the target being in that location during treatment may be very 
small. Ad-hoc adjustments are therefore often made, but this makes 
it very difficult to assure robustness or even estimate the level of 
robustness of the modified plan. Finally, with painted dose 
distributions, no simple margins recipes exist. 
How are we going to deal with these problems? Well there is only one 
good solution, margins have to go! By incorporating the knowledge 
about residual uncertainty distributions directly into IMRT planning, 
robust dose distributions are sculpted that take the actual shape of 
the dose distribution and the location of organs at risk into account 
when generating a ‘margin’. A number of publications have 
investigated this approach, demonstrating the possibility to develop 
plans that are just as robust as their margin-based counterparts, but 
with much lower exposure of the organs at risk. The resulting plans 
look very sensible, e.g., similar to integrated boost approaches with 
reduced margins towards organs at risk but with guaranteed 
robustness. And why is not everybody using this approach if it is 
clearly better? This is because so far planning system vendors have 
refused to invest in this approach. Hopefully this situation will change 
soon. 
 
 
 
 
 
 
